Breast cancer

Disease · 8 studies in the Atlas

Hormone-receptor-positive advanced breast cancer becomes resistant to endocrine therapy partly by activating mTOR; adding the rapalog everolimus to exemestane delays progression (BOLERO-2: progression-free survival roughly doubled, without a significant overall-survival benefit).

A cancer where a rapalog is used with hormone therapy. Hormone-driven advanced breast cancer can become resistant to standard hormone therapy partly by switching on mTOR signaling as a workaround. Adding the mTOR-blocking drug everolimus to hormone therapy roughly doubled the time before the cancer grew again, although it did not significantly lengthen overall survival.

BOLERO-2: progression-free survival benefit, no clear overall-survival benefit, meaningful toxicity – a resistance-delaying rather than curative effect.

TL;DR. Breast cancer appears in 8 curated studies in Oliver's mTOR Atlas: 3 in people (3 human studies); 2 in animal models; 3 at the molecular level (cells, biochemistry, structure). It has 1 interaction in the curated pathway model.

In the pathway model

1 interaction in the curated mTOR pathway model. Each row is a claim with the evidence behind it; the evidence code is the kind of study, not its quality.

Evidence at a glance

Human studies in the Atlas

3 studies in people, newest first. Design and population as recorded for each study; the evidence code is the kind of study, not its quality.

Studies

Related entities

Barton, O. (2026). Breast cancer [Entity page]. In Oliver's mTOR Atlas [Data set]. https://mtor-atlas.org/disease/breast-cancer/ · Dataset DOI 10.5281/zenodo.22059963

@misc{atlas_disease_breast_cancer,
  author       = {Barton, Oliver},
  title        = {{Oliver's mTOR Atlas}: Breast cancer},
  howpublished = {Entity page in a data set},
  year         = {2026},
  url          = {https://mtor-atlas.org/disease/breast-cancer/},
  doi          = {10.5281/zenodo.22059963}
}